Wall Street brokerages expect AmerisourceBergen Corp. (NYSE:ABC) to post earnings per share (EPS) of $1.35 for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for AmerisourceBergen’s earnings. The lowest EPS estimate is $1.23 and the highest is $1.39. AmerisourceBergen posted earnings per share of $1.36 in the same quarter last year, which indicates a negative year over year growth rate of 0.7%. The business is expected to report its next earnings results before the market opens on Tuesday, February 6th.

According to Zacks, analysts expect that AmerisourceBergen will report full-year earnings of $6.19 per share for the current year, with EPS estimates ranging from $6.00 to $6.64. For the next financial year, analysts expect that the company will report earnings of $6.81 per share, with EPS estimates ranging from $6.49 to $7.31. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover AmerisourceBergen.

AmerisourceBergen (NYSE:ABC) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.01. AmerisourceBergen had a net margin of 0.27% and a return on equity of 56.29%. The business had revenue of $39.12 billion during the quarter, compared to analyst estimates of $40.10 billion. During the same period last year, the firm posted $1.30 EPS. The company’s revenue was up 4.2% on a year-over-year basis.

A number of brokerages have issued reports on ABC. Zacks Investment Research lowered shares of AmerisourceBergen from a “buy” rating to a “hold” rating in a report on Monday. Evercore ISI began coverage on shares of AmerisourceBergen in a report on Thursday, January 4th. They set an “outperform” rating and a $105.00 price objective for the company. Leerink Swann set a $105.00 price objective on shares of AmerisourceBergen and gave the company a “buy” rating in a report on Tuesday, January 2nd. Goldman Sachs Group raised shares of AmerisourceBergen from a “neutral” rating to a “buy” rating in a report on Friday, December 15th. Finally, Cowen set a $107.00 price objective on shares of AmerisourceBergen and gave the company a “buy” rating in a report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $95.96.

Shares of AmerisourceBergen (ABC) traded up $0.55 on Wednesday, reaching $99.55. 1,869,700 shares of the company’s stock were exchanged, compared to its average volume of 1,400,190. The company has a debt-to-equity ratio of 1.83, a quick ratio of 0.48 and a current ratio of 0.91. AmerisourceBergen has a twelve month low of $71.90 and a twelve month high of $100.67. The stock has a market cap of $21,960.00, a price-to-earnings ratio of 61.45, a P/E/G ratio of 1.68 and a beta of 0.99.

In other AmerisourceBergen news, Chairman Steven H. Collis sold 21,350 shares of AmerisourceBergen stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $76.94, for a total transaction of $1,642,669.00. Following the completion of the transaction, the chairman now directly owns 260,226 shares of the company’s stock, valued at $20,021,788.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard W. Gochnauer sold 2,000 shares of AmerisourceBergen stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $96.54, for a total transaction of $193,080.00. Following the transaction, the director now directly owns 12,947 shares of the company’s stock, valued at $1,249,903.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 203,823 shares of company stock valued at $17,145,148. 27.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in AmerisourceBergen by 2.0% during the second quarter. Vanguard Group Inc. now owns 15,653,245 shares of the company’s stock worth $1,479,701,000 after buying an additional 304,628 shares during the period. JPMorgan Chase & Co. boosted its stake in AmerisourceBergen by 107.3% during the third quarter. JPMorgan Chase & Co. now owns 5,363,429 shares of the company’s stock worth $434,385,000 after buying an additional 2,776,287 shares during the period. Wells Fargo & Company MN boosted its stake in AmerisourceBergen by 11.4% during the third quarter. Wells Fargo & Company MN now owns 3,726,377 shares of the company’s stock worth $308,358,000 after buying an additional 381,936 shares during the period. FIL Ltd boosted its stake in AmerisourceBergen by 14.4% during the second quarter. FIL Ltd now owns 3,477,157 shares of the company’s stock worth $328,696,000 after buying an additional 437,132 shares during the period. Finally, Harding Loevner LP boosted its stake in AmerisourceBergen by 89.6% during the third quarter. Harding Loevner LP now owns 3,166,794 shares of the company’s stock worth $134,939,000 after buying an additional 1,496,761 shares during the period. 67.83% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/17/1-35-eps-expected-for-amerisourcebergen-corp-abc-this-quarter.html.

AmerisourceBergen Company Profile

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.

Get a free copy of the Zacks research report on AmerisourceBergen (ABC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AmerisourceBergen (NYSE:ABC)

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.